Literature DB >> 11574579

Use of random amplified polymorphic DNA PCR to examine epidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from patients with cystic fibrosis.

J W Krzewinski1, C D Nguyen, J M Foster, J L Burns.   

Abstract

Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans have been increasingly recognized as a cause of respiratory tract colonization in cystic fibrosis (CF). Although both organisms have been associated with progressive deterioration of pulmonary function, demonstration of causality is lacking. To examine the molecular epidemiology of S. maltophilia and A. xylosoxidans in CF, isolates from patients monitored for up to 2 years were fingerprinted using a PCR-based randomly amplified polymorphic DNA (RAPD-PCR) method. Sixty-one of 69 CF centers screened had 183 S. maltophilia culture-positive patients, and 46 centers had 92 A. xylosoxidans-positive patients. At least one isolate from each patient was genotyped, and patients with > or =10 positive cultures (12 S. maltophilia cultures, 15 A. xylosoxidans cultures) had serial isolates genotyped. In addition, centers with multiple culture-positive patients were examined for evidence of shared clones. There were no instances of shared genotypes among different CF centers. Some patients demonstrated isolates with a single genotype throughout the observation period, and others had intervening or sequential genotypes. At the six centers with multiple S. maltophilia culture-positive patients and the seven centers with multiple A. xylosoxidans-positive patients, there were three and five instances of shared genotypes, respectively. The majority of shared isolates were from pairs who were siblings or otherwise epidemiologically linked. These findings suggest RAPD-PCR typing can distinguish unique CF isolates of S. maltophilia and A. xylosoxidans, person-to-person transmission may occur, there are not a small number of clones infecting CF airways, and patients with long-term colonization may either have a persistent organism or may acquire additional organisms over time.

Entities:  

Mesh:

Year:  2001        PMID: 11574579      PMCID: PMC88395          DOI: 10.1128/JCM.39.10.3597-3602.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  40 in total

1.  Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.

Authors:  J L Burns; J M Van Dalfsen; R M Shawar; K L Otto; R L Garber; J M Quan; A B Montgomery; G M Albers; B W Ramsey; A L Smith
Journal:  J Infect Dis       Date:  1999-05       Impact factor: 5.226

2.  Investigation of an outbreak of wound infections due to Alcaligenes xylosoxidans transmitted by chlorhexidine in a burns unit.

Authors:  H Vu-Thien; J C Darbord; D Moissenet; C Dulot; J B Dufourcq; P Marsol; A Garbarg-Chenon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-10       Impact factor: 3.267

3.  Evidence of nosocomial Stenotrophomonas maltophilia cross-infection in a neonatology unit analyzed by three molecular typing methods.

Authors:  D Garciá de Viedma; M Marín; E Cercenado; R Alonso; M Rodríguez-Créixems; E Bouza
Journal:  Infect Control Hosp Epidemiol       Date:  1999-12       Impact factor: 3.254

4.  In vitro susceptibility of Alcaligenes denitrificans subsp. xylosoxidans to 24 antimicrobial agents.

Authors:  Y Glupczynski; W Hansen; J Freney; E Yourassowsky
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

5.  Occurrence and antimicrobial susceptibility of gram-negative nonfermentative bacilli in cystic fibrosis patients.

Authors:  J D Klinger; M J Thomassen
Journal:  Diagn Microbiol Infect Dis       Date:  1985-03       Impact factor: 2.803

6.  Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.

Authors:  B W Ramsey; M S Pepe; J M Quan; K L Otto; A B Montgomery; J Williams-Warren; M Vasiljev-K; D Borowitz; C M Bowman; B C Marshall; S Marshall; A L Smith
Journal:  N Engl J Med       Date:  1999-01-07       Impact factor: 91.245

7.  Infections caused by Pseudomonas maltophilia. Expanding clinical spectrum.

Authors:  R R Muder; V L Yu; J S Dummer; C Vinson; R M Lumish
Journal:  Arch Intern Med       Date:  1987-09

8.  Hospital epidemiology of Pseudomonas aeruginosa from patients with cystic fibrosis.

Authors:  D P Speert; M E Campbell
Journal:  J Hosp Infect       Date:  1987-01       Impact factor: 3.926

9.  Associated mortality and clinical characteristics of nosocomial Pseudomonas maltophilia in a university hospital.

Authors:  A J Morrison; K K Hoffmann; R P Wenzel
Journal:  J Clin Microbiol       Date:  1986-07       Impact factor: 5.948

10.  Microbiology of sputum from patients at cystic fibrosis centers in the United States.

Authors:  J L Burns; J Emerson; J R Stapp; D L Yim; J Krzewinski; L Louden; B W Ramsey; C R Clausen
Journal:  Clin Infect Dis       Date:  1998-07       Impact factor: 9.079

View more
  26 in total

1.  Molecular epidemiology of Stenotrophomonas maltophilia isolated from cystic fibrosis patients.

Authors:  Miles Denton; Kevin G Kerr
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

2.  Are probiotics detectable in human feces after oral uptake by healthy volunteers?

Authors:  Martina Prilassnig; Christoph Wenisch; Florian Daxboeck; Gebhard Feierl
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

Review 3.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

4.  Prevalence and Outcomes of Achromobacter Species Infections in Adults with Cystic Fibrosis: a North American Cohort Study.

Authors:  B D Edwards; J Greysson-Wong; R Somayaji; B Waddell; F J Whelan; D G Storey; H R Rabin; M G Surette; M D Parkins
Journal:  J Clin Microbiol       Date:  2017-04-26       Impact factor: 5.948

5.  Development of rapid phenotypic system for the identification of Gram-negative oxidase-positive bacilli in resource-limited settings.

Authors:  Mahmooda Kazmi; Adnan Khan; Shahana Urooj Kazmi
Journal:  J Biosci       Date:  2013-06       Impact factor: 1.826

6.  Long-Term Rasamsonia argillacea Complex Species Colonization Revealed by PCR Amplification of Repetitive DNA Sequences in Cystic Fibrosis Patients.

Authors:  Abdelmounaim Mouhajir; Olivier Matray; Sandrine Giraud; Laurent Mély; Christophe Marguet; Isabelle Sermet-Gaudelus; Solène Le Gal; Franck Labbé; Christine Person; Françoise Troussier; Jean-Jacques Ballet; Gilles Gargala; Rachid Zouhair; Marie-Elisabeth Bougnoux; Jean-Philippe Bouchara; Loïc Favennec
Journal:  J Clin Microbiol       Date:  2016-09-07       Impact factor: 5.948

7.  Shared genotypes of Achromobacter xylosoxidans strains isolated from patients at a cystic fibrosis rehabilitation center.

Authors:  Sabine Van Daele; Rita Verhelst; Geert Claeys; Gerda Verschraegen; Hilde Franckx; Leen Van Simaey; Catharine de Ganck; Frans De Baets; Mario Vaneechoutte
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

8.  Clinical Features, Antibiotic Susceptibility Profiles, and Outcomes of Infectious Keratitis Caused by Achromobacter xylosoxidans.

Authors:  Oriel Spierer; Pedro F Monsalve; Terrence P OʼBrien; Eduardo C Alfonso; Daniel Gologorsky; Darlene Miller
Journal:  Cornea       Date:  2016-05       Impact factor: 2.651

9.  Molecular characterization of Achromobacter isolates from cystic fibrosis and non-cystic fibrosis patients in Madrid, Spain.

Authors:  Laura Barrado; Patricia Brañas; M Ángeles Orellana; M Teresa Martínez; Gloria García; Joaquín R Otero; Fernando Chaves
Journal:  J Clin Microbiol       Date:  2013-03-27       Impact factor: 5.948

Review 10.  Infection control in cystic fibrosis.

Authors:  Lisa Saiman; Jane Siegel
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.